Skip to main content
Journal cover image

Interferon alfa-2a in the treatment of cutaneous T cell lymphoma.

Publication ,  Journal Article
Olsen, EA; Rosen, ST; Vollmer, RT; Variakojis, D; Roenigk, HH; Diab, N; Zeffren, J
Published in: J Am Acad Dermatol
March 1989

Twenty-two patients with Stages Ia to IVa cutaneous T cell lymphoma were entered into a controlled trial of interferon alfa-2a (Roferon-A). Patients initially received either 3 million IU interferon alfa-2a, or their dosage was escalated to 36 million IU intramuscularly daily for a 10-week induction period. At the end of induction, 14/22 (64%) of patients had an objective antitumor response: three patients had a complete response, ten patients had a partial response (greater than or equal to 50% resolution of clinical disease), and one patient had a minor response. Responders included those with Stages Ia to IVa cutaneous T cell lymphoma, and remissions have lasted at least 4 to 27.5 months. Three patients progressed from a partial to complete response with further treatment, for an overall complete response rate of 27%. Acute flu-like side effects were generally minor and transient. Malaise/fatigue, depression, anorexia, and weight loss were common chronic dose-related side effects and the most frequent reasons for dose reduction or discontinuation of drug. Leukopenia was the most common laboratory side effect and was also dose-related. Recombinant human leukocyte interferon alfa-2a is an effective and well-tolerated single-agent therapy for early and advanced cutaneous T cell lymphoma.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Acad Dermatol

DOI

ISSN

0190-9622

Publication Date

March 1989

Volume

20

Issue

3

Start / End Page

395 / 407

Location

United States

Related Subject Headings

  • T-Lymphocytes
  • Skin Neoplasms
  • Skin
  • Recombinant Proteins
  • Random Allocation
  • Prognosis
  • Middle Aged
  • Male
  • Lymphoma
  • Interferon-alpha
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Olsen, E. A., Rosen, S. T., Vollmer, R. T., Variakojis, D., Roenigk, H. H., Diab, N., & Zeffren, J. (1989). Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol, 20(3), 395–407. https://doi.org/10.1016/s0190-9622(89)70049-9
Olsen, E. A., S. T. Rosen, R. T. Vollmer, D. Variakojis, H. H. Roenigk, N. Diab, and J. Zeffren. “Interferon alfa-2a in the treatment of cutaneous T cell lymphoma.J Am Acad Dermatol 20, no. 3 (March 1989): 395–407. https://doi.org/10.1016/s0190-9622(89)70049-9.
Olsen EA, Rosen ST, Vollmer RT, Variakojis D, Roenigk HH, Diab N, et al. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol. 1989 Mar;20(3):395–407.
Olsen, E. A., et al. “Interferon alfa-2a in the treatment of cutaneous T cell lymphoma.J Am Acad Dermatol, vol. 20, no. 3, Mar. 1989, pp. 395–407. Pubmed, doi:10.1016/s0190-9622(89)70049-9.
Olsen EA, Rosen ST, Vollmer RT, Variakojis D, Roenigk HH, Diab N, Zeffren J. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol. 1989 Mar;20(3):395–407.
Journal cover image

Published In

J Am Acad Dermatol

DOI

ISSN

0190-9622

Publication Date

March 1989

Volume

20

Issue

3

Start / End Page

395 / 407

Location

United States

Related Subject Headings

  • T-Lymphocytes
  • Skin Neoplasms
  • Skin
  • Recombinant Proteins
  • Random Allocation
  • Prognosis
  • Middle Aged
  • Male
  • Lymphoma
  • Interferon-alpha